Fundz

ArrePath, Inc. secured £1 million in a grant from PACE to advance the development of novel antibiotics targeting multidrug-resistant infections.

PRIVATENov 19, 2024

Amount Raised

£1 Million

Round Type

Seed

PrincetonInformation TechnologySoftwareData And AnalyticsScience And Engineering

Description

ArrePath, Inc. has been awarded a £1 million non-dilutive grant from PACE to support its efforts in developing a new class of antibiotics against multidrug-resistant bacterial infections. The funding will help advance their lead program towards IND-enabling studies for complicated urinary tract infections caused by MDR organisms.

Who else raised in Data And Analytics and Science And Engineering around the same time

Companies in the same sectors as ArrePath that raised within 45 days of this round, from Fundz verified event records.

  • Lilt raised $45M on November 15, 2024.
  • Cornerstone AI raised $5M (Series A) on October 30, 2024.
  • Be Biopharma raised $82M (Funding Round) on October 22, 2024.
  • Crusoe raised $600 (Series D) on December 16, 2024.
  • Quantum Brilliance raised $30M (Series A) on December 10, 2024.
  • Axiado raised $60M (Series C) on December 4, 2024.

Who to call at ArrePath, and when

A new round usually means ArrePath is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day ArrePath raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ArrePath, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at ArrePath. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ArrePath

Location

Princeton, New Jersey, United States

About

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ArrePath raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for ArrePath's next move

See what Strategic adds

ArrePath raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.